Unituxin FDA Approval History
FDA Approved: Yes (First approved March 10, 2015)
Brand name: Unituxin
Generic name: dinutuximab
Dosage form: Injection
Company: United Therapeutics Corporation
Treatment for: Neuroblastoma
Unituxin (dinutuximab) is a chimeric monoclonal antibody used for the treatment of pediatric neuroblastoma.
Development timeline for Unituxin
| Date | Article |
|---|---|
| Mar 10, 2015 | Approval FDA Approves Unituxin (dinutuximab) for Pediatric High-Risk Neuroblastoma |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.